Abstracts tagged "prognostic factors and rheumatoid arthritis"

Abstract Number: 451 • 2017 ACR/ARHP Annual Meeting
A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months
Pooneh S. Akhavan¹, Daming Li¹, Sahar Tabatabvakili¹ and Edward C. Keystone², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
Background/Purpose: The present study aimed to develop a matix to predict risk of radiographic progression in patients with early rheumatoid arthritis. The focus of this…
Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting
Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Paul Studenic¹, Farideh Alasti², Daniel Aletaha³, Josef S. Smolen¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].